Innovotech Inc. (TSX Venture Exchange: IOT; OTCQB: IOTCF), a life sciences services and technology company, reported financial results for the first quarter ended March 31, 2026, revealing a 44% decline in revenue to $648,140 from $1.16 million in the same period last year. The decrease was primarily attributed to a change in activities for a large project with a major customer, which had been expected to continue through 2026. The company’s gross profit fell to $202,231, with a gross margin of 31.2%, down from 53.6% in Q1 2025, driven by underutilized capacity as Innovotech maintained staffing and operational readiness in anticipation of the planned customer work.
Innovotech recorded a net and comprehensive loss of $401,295 for the quarter, compared to net income of $63,523 in the prior year. Operating expenses increased year over year, reflecting the integration of Keystone Labs and Innovotech Labs, the relocation of the former Keystone Labs operations to a new facility, and investments in a stronger sales organization. Despite the challenging quarter, the company continues to advance its strategic transformation, including strengthening its leadership and commercial teams and completing its OTCQB listing in the United States.
CEO Craig Milne commented, “Management remains committed to investing in a more diversified, resilient, and scalable platform. The Company is continuing to execute its transformation strategy with a focus on the operational and commercial initiatives required to support long-term growth and reduce revenue concentration risk.” The company maintains a strong liquidity position and a meaningful equity base, providing flexibility to manage near-term volatility while executing its longer-term strategy.
Innovotech specializes in contract research, analytical, and microbial testing within regulated healthcare markets. It is a recognized leader in biofilm science and antimicrobial testing, providing advanced laboratory services for medical device, pharmaceutical, and industrial product development. The company operates through ISO-certified and GMP-accredited laboratories and supports clients across multiple sectors and geographies. Its proprietary MBEC Assay® platform is widely used for high-throughput antimicrobial and antibiotic testing. The company’s unaudited consolidated financial statements and Management’s Discussion and Analysis have been filed on SEDAR+ and the OTCIQ system.
The revenue decline highlights the risks associated with client concentration, as the loss of a major project had a significant impact on financial performance. Management’s focus on expanding service offerings and building a more diversified revenue base aims to mitigate such risks in the future. The company’s investment in operational readiness, while costly in the short term, positions it to capitalize on new opportunities as they arise. For the industry, Innovotech’s challenges underscore the importance of diversification in life sciences services, where reliance on a few large clients can lead to volatility. The company’s ongoing transformation efforts, including enhanced commercial capabilities and expanded laboratory capacity, may strengthen its competitive position and ability to serve a broader client base.
